In this online CME self-learning program:
Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from the leukemias in the United States. It is estimated that about 14,590 people will be diagnosed with the disease in 2013 and will lead to approximately 10,370 deaths. The incidence of AML increases with age; the median age of diagnosis is 66 years. AML is also seen in children, although to a lesser extent than adults, and it appears to have a higher incidence in the Hispanic population. While the incidence of AML has been stable for the past two decades, treatment options have been continuing to advance and guidelines for therapy have been consistently updating to dramatically improve the outlook of patients with AML. Outcomes for 5-year survival in children under 15 years of age are between 45-55% but prognosis of adult care is worse than that of childhood leukemia. Taking all ages into account, the 5-year survival rate varies ranges from 20 and 30%.
Several classes of new drugs are being investigated as an alternative treatment approaches for refractory AML, including ubiquitin-proteasome pathway inhibitors, new novel nucleoside analogs, hypomethylating agents, histone deacetylase inhibitors, and angiogenesis modulators provide a hopeful future for successful AML therapy for refractory patients. Frequent updates to present treatment guidelines, representing an implicit practice gap, along with the burgeoning number of viable, biochemical targets in AML warrant continuing education programming aimed at the specialist that encompass current and potential future treatment options for patients with AML. This program has been designed to bring healthcare professionals’ knowledge of current and emerging treatment strategies for AML up to date and to improve their competence and performance in treating it.
Agenda
Epidemiology of and risk factors for AML |
Symptomology and diagnosis of AML |
Updates in treatment in patients with AML |
Healthcare professionals specializing in: hematology, oncology, and those who otherwise commonly care for patients with AML.
Commercial Support Disclosure: This program is supported by educational grants from Boehringer-Ingelheim.
Release Date: April 28, 2014 -- Expiration Date: April 28, 2016
Faculty: Jonathan Kolitz, MD
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Jonathan Kolitz, MD is a stockholder in Celgene and Amgen, and is consultant for Ariad, Novartis, Sanofi, and Abbott.
Disclosures of Educational Planners: Charles Turck, PharmD has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by educational grants from Boehringer-Ingelheim.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.